Are Cosentyx (secukinumab) and tocilizumab the same kind of drug?
No. Cosentyx and tocilizumab target different immune pathways.
- Cosentyx (secukinumab) is a monoclonal antibody that blocks interleukin-17A (IL‑17A).
- Tocilizumab blocks the interleukin-6 (IL‑6) receptor.
Because they inhibit different cytokines, they are not interchangeable and may work differently depending on the condition being treated.
What diseases are they used for?
Both are used in inflammatory and autoimmune diseases, but the specific indications overlap only partially.
- Cosentyx is used for several IL‑17A–mediated conditions, including plaque psoriasis and psoriatic arthritis, and it is also used in ankylosing spondylitis (and related axial spondyloarthritis indications, depending on local approvals).
- Tocilizumab is used for IL‑6–mediated diseases such as rheumatoid arthritis, and it is also used in certain other inflammatory conditions (with indication details depending on country and patient population).
If you tell me which condition you’re asking about (e.g., psoriasis vs rheumatoid arthritis), I can compare them more directly.
How do their mechanisms differ in practice?
The key similarity is that both are biologics that suppress inflammation by targeting specific immune signals. The key difference is the signal they target:
- Cosentyx: IL‑17A blockade tends to be linked to reducing pathways involved in psoriasis and other IL‑17–driven inflammation.
- Tocilizumab: IL‑6 receptor blockade can affect a broader set of inflammatory responses driven by IL‑6, including effects on acute-phase markers and systemic inflammation.
Are they used together or switched for the same patient?
Clinicians sometimes switch between biologics when a patient doesn’t respond, loses response, or has side effects. But because they target different cytokines, switching is a change in mechanism rather than a direct “same drug” substitution.
Whether switching from one to the other makes sense depends on:
- the exact diagnosis,
- prior biologic exposure,
- disease activity,
- safety history, and
- guideline recommendations in that indication.
Safety and monitoring: are they similar?
They can have overlapping “biologic” class concerns (like infection risk), but the details differ because IL‑17A and IL‑6 biology are different. For example, IL‑6 blockade is commonly associated with changes in lab markers (such as lipid levels and liver enzymes) that require monitoring, while IL‑17A blockade can be associated with risks like fungal infections (notably candidiasis) in some patients.
If you share the condition and what safety issue you’re worried about, I can tailor the comparison.
Quick takeaway
They are both biologic anti-inflammatory antibodies, but they are not similar in the sense of being the same drug or same target: Cosentyx blocks IL‑17A, while tocilizumab blocks IL‑6 signaling.
Sources: none provided in the prompt.